AbbVie Announces Acquisition of Apogee Therapeutics for $10.9 Billion

AbbVie has agreed to acquire Apogee Therapeutics in a $10.9 billion all-cash deal, enhancing its immunology portfolio with clinical-stage therapies targeting inflammatory and immune diseases such as atopic dermatitis and asthma.

By Proactive Mon, June 22, 2026 at 5:04 PM GMT+3 1 min read · Yahoo Finance · June 22, 2026, 14:04 UTC

AbbVie Announces Acquisition of Apogee Therapeutics for $10.9 Billion

Tickers: $ABBV $APGE

Topics: clinical-stage_therapies immunology pharmaceuticals

Read the full article at Yahoo Finance

More World news

California Supreme Court to Rule on Insurance Overcharge Liability Under Proposition 103 PR Newswire · November 12, 2026, 18:44 UTC
Federal Court Orders Veterans Guardian to Pay Treble Damages to Disabled Veteran Class PR Newswire · November 12, 2026, 18:41 UTC
AIRO Group Holdings Reaffirms 2026 Revenue Growth Guidance Amid $200 Million Drone Backlog Seeking Alpha · November 12, 2026, 18:40 UTC
Nvidia CEO Jensen Huang Resigns Amid Personal Scandal, Raising Uncertainty for Open Source AI Strategy TechCrunch · November 12, 2026, 18:39 UTC
Vor Bio and RemeGen Expand Collaboration for Autoimmune Disease Therapy Seeking Alpha · November 12, 2026, 18:35 UTC
EnterpriseDB Hires CMRD Engineering Team to Strengthen Sovereign AI Governance PR Newswire · November 12, 2026, 18:36 UTC
Alliant Credit Union Executive Meredith Ritchie Named 2027 Chicago Titan 100 Honoree PR Newswire · November 12, 2026, 18:36 UTC
Fed's Schmid Argues Construction Productivity is Key to Housing Affordability Over Interest Rate Cuts Seeking Alpha · November 12, 2026, 18:33 UTC
PROG Holdings Reports 59% GMV Growth and Announces $100 Million Share Repurchase Program Motley Fool · November 12, 2026, 18:30 UTC
Corteva Shares Plunge Over Q3 Earnings Miss and Pricing Pressures Motley Fool · November 12, 2026, 18:31 UTC